Tag:

Sanofi

Latest Headlines

Latest Headlines

Bristol-Myers, Sanofi catch a break in Plavix marketing case

Bristol-Myers Squibb and Sanofi scored a victory in a False Claims Act marketing case over its blood-thinner, Plavix, as a federal judge in New Jersey tossed out some allegations from a former Sanofi sales rep that the company made misleading statements about the med to gain more Medicare and Medicare coverage.

Sanofi adds its sales heft to Relypsa's forthcoming patiromer launch

Sanofi has signed up to help Relypsa bring its lead drug patiromer to market. The treatment for hyperkalemia, pegged as a $1.4 billion blockbuster by analysts, is due for an FDA thumbs-up in October.

The top 5 vaccine makers by 2014 revenue

A recent EvaluatePharma analysis predicts that the top four vaccine makers by 2020 are expected to be within less than one percentage point of market share from each other, and last year's developments in the field may have set the stage for that contest. Here, we break down the top 5 vaccines producers of 2014.

Sanofi takes another stab at cancer with Evotec, Apeiron checkpoint partnership

Three days ago Sanofi expanded its tight R&D relationship with Evotec to take on cell-replacement treatments for diabetes. And the pharma giant picked up this morning where it left off, adding an immuno-oncology pact with Evotec that also brings Austria's Apeiron Biologics into the mix.

Sanofi launches fast-acting, high-concentration insulin med Toujeo in the U.K.

A longer-acting version of the world's best-selling diabetes drug is now available in the U.K. Sanofi announced the availability of the long-acting basal insulin med Toujeo in the country. Containing 300 units of insulin glargine per milliliter, the drug is a three times more concentrated reformulation of the company's blockbuster Lantus, which had revenues of about $7 billion last year.

Sanofi deepens its Evotec ties with a $330M diabetes deal

Sanofi is expanding its relationship with close partner Evotec, signing a deal worth up to $330 million to collaborate on cell-replacement therapies for diabetes.

Surprise! It's a DTC campaign for Sanofi and MannKind's Afrezza

There's been lots of hullaballoo surrounding Sanofi and MannKind's launch of inhaled insulin Afrezza, but for the arrival of the pair's first DTC campaign? Not so much.

Sanofi and MannKind launch Afrezza DTC ad campaign in stealth mode

Surprise! It's a DTC campaign for Sanofi and Mannkind's Afrezza. The low-key ad launch of "Surprise, It's Insulin" came with little fanfare, unlike the media and industry scuttlebutt surrounding the drug itself, which has been closely watched and analyzed for more than a year.

Sales of diabetes drugs in Japan are a key H2 performance gauge, Sanofi CEO says

Olivier Brandicourt, CEO of Sanofi, gave his thoughts on the July 30 earnings call about trying to launch a simplification program in the midst of high-profile global rollouts, competition and dealmaking. He also picked one contest to watch in Japan that may be a good gauge of the company's performance on all counts.

China's ZAI Lab in-licenses global rights on Sanofi NSCLC candidate

China's ZAI Lab has in-licensed a novel multi-kinase inhibitor aimed at a non-small cell lung cancer candidate from Sanofi as the firm led by well-known biotech executive Samantha Du builds its on deep Greater China trial and regulatory experience.